Summit Therapeutics (NASDAQ:SMMT - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.08), Zacks reports. The company had revenue of $0.20 million during the quarter.
Summit Therapeutics Price Performance
NASDAQ SMMT traded up $0.19 on Thursday, reaching $18.49. The company had a trading volume of 2,200,069 shares, compared to its average volume of 2,497,372. The firm has a market capitalization of $13.64 billion, a PE ratio of -66.03 and a beta of -0.88. The firm has a 50-day moving average of $19.93 and a 200-day moving average of $19.19. Summit Therapeutics has a 1 year low of $2.10 and a 1 year high of $33.89.
Wall Street Analysts Forecast Growth
SMMT has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $44.00 target price on shares of Summit Therapeutics in a research report on Tuesday. StockNews.com downgraded Summit Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday. Jefferies Financial Group started coverage on Summit Therapeutics in a report on Friday, December 6th. They set a "buy" rating and a $31.00 target price for the company. Truist Financial began coverage on shares of Summit Therapeutics in a report on Wednesday, January 8th. They issued a "buy" rating and a $35.00 price target on the stock. Finally, Wells Fargo & Company started coverage on shares of Summit Therapeutics in a research report on Wednesday, December 11th. They set an "overweight" rating and a $30.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Summit Therapeutics has an average rating of "Moderate Buy" and an average price target of $33.57.
Check Out Our Latest Research Report on Summit Therapeutics
About Summit Therapeutics
(
Get Free Report)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Read More
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
